RSV Treatment Shortage Leaves Parents Frustrated and Worried
Parents of infants and toddlers are struggling to obtain the new preventative drug, nirsevimab, for respiratory syncytial virus (RSV) due to high demand, supply issues, and confusion over insurance coverage. Nirsevimab, approved by the FDA, is recommended for babies under 8 months old and children between 8 and 19 months old who are vulnerable to severe RSV disease. However, there is a shortage of doses, leading to prioritization for high-risk infants. Some parents have faced difficulties in booking appointments and receiving clear information about eligibility and insurance coverage. Despite the challenges, parents are taking precautions to protect their children from RSV.